All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elezanumab
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ABT-555
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Elezanumab is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). Elezanumab is being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sevoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: VPX638
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 11, 2020
Details:
The Phase II SBIR funding will be used to develop a formulation of VPX638 (sevoflurane) and to further characterize the anti-inflammatory and analgesic profile in animal disease models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LSALT peptide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger ARDS and acute kidney injury (AKI) in patients infected with COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-04457845
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PF-04457845
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $410.0 million Upfront Cash: $35.0 million
Deal Type: Acquisition October 26, 2020
Details:
Under the terms of the agreement, SpringWorks has assigned and exclusively licensed all assets relating to its FAAH inhibitor program to Jazz, including SpringWorks' proprietary FAAH inhibitor PF-04457845 and its license agreement with Pfizer, Inc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Ghrelin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: OXE103
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The Randomized, placebo controlled phase 2 study aims to reduce symptom burden with OXE103 treatment. Measures of cognition and balance will also be tracked to provide objective assessment of recovery.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NTX-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Company announced activation of it first clinical site of its Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Patients with Acute Single Transected Peripheral Nerve Injuries of the Upper Extremities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The FDA response provided clear feedback on the proposed plan and outlined the critical steps to test XRx-101 in patients with COVID-19 infection to treat acute kidney injury (“AKI”).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Suramin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: REX Health Ventures
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020
Details:
RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
This filing initiates formal communications with the U.S. FDA regarding development of the Company’s proprietary formulation of XRx-101 (Oxypurinol) for the treatment and prevention of acute kidney injury (AKI) associated with COVID-19 coronavirus infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020
Details:
XRx-101 is a proprietary of xanthine oxidase inhibitor oxypurinol. The study provides clues about the potential of XRx-101 as a treatment to suppress the severity of the coronavirus / COVID-19 infection.